Somewhat Favorable Media Coverage Somewhat Unlikely to Impact ADMA Biologics (ADMA) Share Price

Media stories about ADMA Biologics (NASDAQ:ADMA) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ADMA Biologics earned a news impact score of 0.03 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.3142660303953 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Shares of NASDAQ:ADMA traded up $0.05 on Friday, hitting $4.91. The company’s stock had a trading volume of 2,225,505 shares, compared to its average volume of 295,934. The stock has a market cap of $220.24 million, a P/E ratio of -2.57 and a beta of 2.11. The company has a quick ratio of 3.60, a current ratio of 4.92 and a debt-to-equity ratio of 1.76. ADMA Biologics has a 1 year low of $2.01 and a 1 year high of $5.70.

Get ADMA Biologics alerts:

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Monday, May 14th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.27) by ($0.08). The firm had revenue of $4.04 million for the quarter, compared to analysts’ expectations of $7.47 million. ADMA Biologics had a negative net margin of 101.93% and a negative return on equity of 88.31%. equities research analysts expect that ADMA Biologics will post -1.34 EPS for the current fiscal year.

Several analysts have weighed in on the company. LADENBURG THALM/SH SH lowered their price target on ADMA Biologics to $7.50 and set a “buy” rating on the stock in a report on Wednesday, June 13th. ValuEngine raised ADMA Biologics from a “sell” rating to a “hold” rating in a report on Monday, May 14th. Finally, Maxim Group set a $10.00 price target on ADMA Biologics and gave the company a “buy” rating in a report on Tuesday, April 24th.

In other news, Director Jerrold B. Grossman acquired 20,921 shares of the firm’s stock in a transaction that occurred on Friday, June 8th. The shares were bought at an average cost of $4.78 per share, with a total value of $100,002.38. Following the acquisition, the director now owns 98,007 shares in the company, valued at approximately $468,473.46. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Adam S. Grossman acquired 52,301 shares of the firm’s stock in a transaction that occurred on Friday, June 8th. The shares were purchased at an average cost of $4.78 per share, for a total transaction of $249,998.78. Following the completion of the acquisition, the chief executive officer now owns 32,527 shares in the company, valued at approximately $155,479.06. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 78,222 shares of company stock worth $373,901. 16.90% of the stock is currently owned by insiders.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.